Legend Biotech Corporation (NASDAQ: LEGN), a leading global figure in cell therapy, has unveiled its inaugural Environmental, Social & Governance (ESG) report. This comprehensive document provides an insight into Legend Biotech’s ESG initiatives, aligned with the Sustainable Accounting Standards Board (“SASB”) Biotechnology and Pharmaceutical sector standards, outlining the company’s ESG data collection and disclosure trajectory, and outlining prospective growth areas in its ESG expedition.
Ying Huang, Chief Executive Officer of Legend Biotech, expressed, “At Legend Biotech, our mission revolves around providing life-saving treatments to patients grappling with intractable and incurable diseases. As one of the largest global cell therapy research and development teams, sustainable business practices are fundamental in achieving our mission. We are pleased to present our inaugural ESG report, which underscores our dedication to patients, employees, and communities. This report marks an essential milestone in our ESG journey, and we eagerly anticipate further progress in the years to come.”
Key components of Legend’s ESG program include:
- Caring for Patients, Delivering Transformative Innovations: With a substantial investment exceeding $1 billion in R&D since inception and ongoing collaborations with esteemed academic institutions, major hospitals, and industry giants, Legend Biotech maintains an unwavering commitment to cutting-edge and ethical R&D. The company prioritizes patient access and well-being throughout the treatment continuum by engaging with patient advocacy organizations, investing in commercial presence and production capacity to ensure a robust supply chain, and implementing a comprehensive patient support program.
- Engaging with Employees and Communities: Legend Biotech recognizes that its achievements are attributable to the dedication of a talented and passionate workforce. Notably, based on its most recent annual employee engagement survey, 85% of employees feel their work is meaningful. The company fosters an environment where diverse backgrounds and ideas foster innovation and is dedicated to providing employees with a meaningful career trajectory through focused talent retention, professional development, and community involvement opportunities.
- Fostering Operational Efficiency and Integrity: Operational excellence, employee well-being, and resource optimization are at the forefront of Legend Biotech’s priorities. Robust environmental, health, and safety (EHS) management underscore the company’s commitment to operational efficiency and integrity. Legend Biotech’s newly inaugurated chimeric antigen receptor T-cell (CAR-T) facility in Ghent, Belgium, exemplifies this commitment with state-of-the-art ecological efficiency features. The company ensures the observance of high safety standards across its three U.S. sites, employing measures such as regular inspections, incident and emissions tracking, and comprehensive training. To enhance accountability to patients, shareholders, and the broader business landscape, Legend Biotech has instituted strong corporate governance practices and a multifaceted, risk-based cybersecurity and data privacy program aligned with business objectives.
Legend Biotech’s 2023 ESG Report is accessible on the company’s website in the About section at www.legendbiotech.com.
ABOUT LEGEND BIOTECH
Legend Biotech is a global biotechnology enterprise committed to treating, and ultimately curing, life-threatening ailments. Headquartered in Somerset, New Jersey, the company is pioneering advanced cell therapies across various technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell, and natural killer (NK) cell-based immunotherapy. Leveraging three R&D hubs worldwide, Legend Biotech is dedicated to discovering cutting-edge therapeutics for patients worldwide.
For more information, visit https://legendbiotech.com and follow the company on X (formerly Twitter) and LinkedIn.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Statements in this press release concerning future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements concerning Legend Biotech’s strategies and objectives and the potential benefits of Legend Biotech’s product candidates. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third-party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; competition in general; government, industry, and general product pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) on March 19, 2024, and Legend Biotech’s other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this press release as anticipated, believed, estimated, or expected. Any forward-looking statements contained in this press release speak only as of the date of this press release. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
